Stock OGN ORGANON & CO.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Organon & Co.

Equities

OGN

US68622V1061

Market Closed - Nyse
Other stock markets
 21:00:02 24/06/2024 BST 		5-day change 1st Jan Change
21.12 USD +1.34% Intraday chart for Organon & Co. +3.78% +46.46%
05-24 Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation MT
05-24 Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications for Hlx14 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
La Agencia Europa de Medicamentos (EMA) ha validado las solicitudes de Henlius y Organon para el candidato a biosimilar HLX14 de Prolia ® y Xgeva ® (denosumab)
L’Agence européenne des médicaments (EMA) entérine les dépôts de Henlius et d’Organon pour le candidat biosimilaire HLX14 de Prolia ® et Xgeva ® (denosumab)
Europäische Arzneimittel-Agentur (EMA) validiert Einreichungen von Henlius und Organon für den Prolia ® und Xgeva ® (Denosumab) Biosimilar-Kandidaten HLX14
Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications for Hlx14
Organon Reports Pricing of $1 Billion Senior Notes Offering
Organon Plans Offerings of Secured, Unsecured Senior Notes Totaling $1 Billion
Organon's Q1 Adjusted Earnings, Revenue Rise; 2024 Revenue Guidance, Quarterly Dividend Maintained
Organon & Co. Reports Earnings Results for the First Quarter Ended March 31, 2024
Organon & Co. Provides Earnings Guidance for the Year 2023
Organon & Co Declares Quarterly Dividend on Common Stock, Payable on June 13, 2024
El estudio clínico comparativo de fase 3 del candidato a biosimilar de Prolia ® y Xgeva ® (denosumab) HLX14 alcanzó los criterios de valoración primarios
Klinische Phase-3-Vergleichsstudie zwischen Prolia ® und Xgeva ® (Denosumab) - Biosimilar-Kandidat HLX14 erreicht primäre Endpunkte
L'essai clinique comparatif de phase 3 du candidat biosimilaire de Prolia ® et de Xgeva ® (denosumab) HLX14 remplit les critères d'évaluation primaires
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint
Aurobindo Pharma Gets US FDA Final Nod for Mometasone Furoate Monohydrate Nasal Spray
Philips : une nouvelle directrice financière en octobre
New York attorney general urges stronger safety warning on asthma drug Singulair
Organon's Hadlima Chosen by VA as Substitute for Humira
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OGN Stock
  4. News Organon & Co.
  5. Other languages